{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:51:22Z","timestamp":1787842282556,"version":"build-2784847793"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100030774","name":"Sociedade Brasileira de Reumatologia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40744-024-00730-w","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T07:49:39Z","timestamp":1734594579000},"page":"123-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High-Titer Rheumatoid Factor is Associated with Worse Clinical Outcomes and Higher Needs for Advanced Therapies in Rheumatoid Arthritis Under Real-Life Conditions"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2930-8088","authenticated-orcid":false,"given":"Victor Davi R. S.","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula M. G.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claiton V.","family":"Brenol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e2nio A.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina R.","family":"Bonfiglioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia R.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoel B.","family":"B\u00e9rtolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"de F\u00e1tima L. C. Sauma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Fernanda B. R.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Louzada-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina D. N.","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e3o C.","family":"Radominski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia Maria H.","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleandro P.","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldo R.","family":"Castelar-Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"730_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:1\u201310.","journal-title":"Nat Rev Dis Primers"},{"key":"730_CR2","first-page":"1","volume":"110","author":"MAM van Delft","year":"2020","unstructured":"van Delft MAM, Huizinga TWJ. An overview of autoantibodies in rheumatoid arthritis. J Autoimmun. 2020;110:1\u201311.","journal-title":"J Autoimmun"},{"key":"730_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1155\/2013\/726598","volume":"35","author":"F Ingegnoli","year":"2013","unstructured":"Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers. 2013;35:727\u201334.","journal-title":"Dis Markers"},{"key":"730_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"730_CR5","first-page":"5","volume":"51","author":"J Kay","year":"2012","unstructured":"Kay J, Upchurch KS. ACR\/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (United Kingdom). 2012;51:5\u20139.","journal-title":"Rheumatology (United Kingdom)."},{"key":"730_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jbspin.2017.02.015","volume":"85","author":"TD de Jong","year":"2018","unstructured":"de Jong TD, Sellam J, Agca R, et al. A multi-parameter response prediction model for rituximab in rheumatoid arthritis. Joint Bone Spine. 2018;85:219\u201326.","journal-title":"Joint Bone Spine"},{"key":"730_CR7","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/art.30233","volume":"63","author":"J Sellam","year":"2011","unstructured":"Sellam J, Hendel-Chavez H, Rouanet S, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011;63:933\u20138.","journal-title":"Arthritis Rheum"},{"key":"730_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-017-1445-3","volume":"19","author":"VC Rom\u00e3o","year":"2017","unstructured":"Rom\u00e3o VC, Vital EM, Fonseca JE, Buch MH. Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? Arthritis Res Ther. 2017;19:1\u201313.","journal-title":"Arthritis Res Ther"},{"key":"730_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-017-1266-4","volume":"19","author":"K Albrecht","year":"2017","unstructured":"Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res Ther. 2017;19:1\u20138.","journal-title":"Arthritis Res Ther"},{"key":"730_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2022","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2022;82:3\u201318.","journal-title":"Ann Rheum Dis"},{"key":"730_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","volume":"30","author":"H Yamanaka","year":"2020","unstructured":"Yamanaka H, Tanaka E, Nakajima A, et al. A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options. Mod Rheumatol. 2020;30:1\u20136.","journal-title":"Mod Rheumatol"},{"key":"730_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/25785826.2021.1928383","volume":"45","author":"R Watanabe","year":"2022","unstructured":"Watanabe R, Hashimoto M, Murata K, et al. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunol Med. 2022;45:35\u201344.","journal-title":"Immunol Med"},{"key":"730_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.semarthrit.2011.09.007","volume":"41","author":"YK Sung","year":"2012","unstructured":"Sung YK, Cho SK, Choi CB, et al. Korean observational study network for arthritis (KORONA): establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea. Semin Arthritis Rheum. 2012;41:745\u201351.","journal-title":"Semin Arthritis Rheum"},{"key":"730_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.reuma.2018.10.002","volume":"16","author":"\u00c1 Acosta-M\u00e9rida","year":"2020","unstructured":"Acosta-M\u00e9rida \u00c1, Naranjo A, Rodr\u00edguez-Lozano C. Prognostic factors for sustained remission in a \u201creal life\u201d cohort of rheumatoid arthritis patients. Reumatol Clin. 2020;16:405\u20139.","journal-title":"Reumatol Clin"},{"key":"730_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73:62\u20138.","journal-title":"Ann Rheum Dis"},{"key":"730_CR16","first-page":"S96","volume":"34","author":"JM Kremer","year":"2016","unstructured":"Kremer JM. The Corrona US registry of rheumatic and autoimmune diseases. Clin Exp Rheumatol. 2016;34:S96\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"730_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00296-022-05258-2","volume":"43","author":"TA Gheita","year":"2023","unstructured":"Gheita TA, Raafat HA, El-Bakry SA, et al. Rheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): nationwide presentation and worldwide stance. Rheumatol Int. 2023;43:667\u201376.","journal-title":"Rheumatol Int"},{"key":"730_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ejr.2022.04.004","volume":"44","author":"N Sobhy","year":"2022","unstructured":"Sobhy N, Ghoniem SA, Eissa BM, et al. Disease characteristics in high versus low titers of rheumatoid factor or anti-citrullinated peptide antibody in rheumatoid arthritis patients. Egypt Rheumatol. 2022;44:325\u20138.","journal-title":"Egypt Rheumatol"},{"key":"730_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1759720X20937132","volume":"12","author":"K Thomas","year":"2020","unstructured":"Thomas K, Lazarini A, Kaltsonoudis E, et al. Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. Ther Adv Musculoskelet Dis. 2020;12:1\u201312.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"730_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42358-018-0001-4","volume":"58","author":"GR Castelar-Pinheiro","year":"2018","unstructured":"Castelar-Pinheiro GR, Vargas-Santos AB, de Albuquerque CP, et al. The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil. Adv Rheumatol. 2018;58:1\u20139.","journal-title":"Adv Rheumatol"},{"key":"730_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/annrheumdis-2012-202779","volume":"72","author":"D Van der Heijde","year":"2013","unstructured":"Van der Heijde D, van der Helm-van Mil AHM, Aletaha D, et al. EULAR definition of erosive disease in light of the 2010 ACR\/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis. 2013;72:479\u201381.","journal-title":"Ann Rheum Dis"},{"key":"730_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/acr.24071","volume":"72","author":"E Alemao","year":"2020","unstructured":"Alemao E, Bao Y, Weinblatt ME, et al. Association of seropositivity and mortality in rheumatoid arthritis and the impact of treatment with disease-modifying antirheumatic drugs: results from a real-world study. Arthritis Care Res (Hoboken). 2020;72:176\u201383.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"730_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9020475","volume":"9","author":"Y Ishikawa","year":"2020","unstructured":"Ishikawa Y, Terao C. The impact of cigarette smoking on risk of rheumatoid arthritis: a narrative review. Cells. 2020;9:1\u201311.","journal-title":"Cells"},{"key":"730_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10030382","volume":"10","author":"JA Valero-Jaimes","year":"2021","unstructured":"Valero-Jaimes JA, L\u00f3pez-Gonz\u00e1lez R, Mart\u00edn-Mart\u00ednez MA, et al. Body mass index and disease activity in chronic inflammatory rheumatic diseases: results of the cardiovascular in rheumatology (Carma) project. J Clin Med. 2021;10:1\u201311.","journal-title":"J Clin Med"},{"issue":"1271","key":"730_CR25","first-page":"2","volume":"81","author":"E Hannech","year":"2022","unstructured":"Hannech E, Ben Tekaya A, Saidane O, et al. AB0291 comorbidities profiles in seropositive rheumatoid arthritis versus seronegative rheumatoid arthritis. Ann Rheum Dis. 2022;81(1271):2\u20131272.","journal-title":"Ann Rheum Dis"},{"key":"730_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/acr.21749","volume":"65","author":"A Wesley","year":"2013","unstructured":"Wesley A, Bengtsson C, Elkan A, Klareskog L, Alfredsson L, Wedr\u00e9n S. Association between body mass index and anti\u2013citrullinated protein antibody\u2013positive and anti\u2013citrullinated protein antibody\u2013negative rheumatoid arthritis: results from a population-based case\u2013control study. Arthritis Care Res (Hoboken). 2013;65:107\u201312.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"730_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.amjms.2022.12.029","volume":"365","author":"A Cawley","year":"2023","unstructured":"Cawley A, Bhalla S, Floresca R, Alvarado L, Dihowm F. Disease profile of rheumatoid arthritis and its complications in Hispanic population. Am J Med Sci. 2023;365:337\u201344.","journal-title":"Am J Med Sci"},{"key":"730_CR28","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.amjmed.2013.09.002","volume":"126","author":"JD Greenberg","year":"2013","unstructured":"Greenberg JD, Spruill TM, Shan Y, et al. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med. 2013;126:1089\u201398.","journal-title":"Am J Med"},{"key":"730_CR29","first-page":"1480","volume":"34","author":"TR Mikuls","year":"2007","unstructured":"Mikuls TR, Kazi S, Cipher D, et al. The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis. J Rheumatol. 2007;34:1480\u20134.","journal-title":"J Rheumatol"},{"key":"730_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42358-018-0045-5","volume":"59","author":"SB Rocha","year":"2019","unstructured":"Rocha SB, Baldo DC, Andrade LEC. Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Adv Rheumatol. 2019;59:1\u201313.","journal-title":"Adv Rheumatol"},{"key":"730_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/diagnostics12071773","volume":"12","author":"M Uriarte Ecenarro","year":"2022","unstructured":"Uriarte Ecenarro M, Useros D, Alfranca A, Tejedor R, Gonz\u00e1lez-Alvaro I, Garc\u00eda-Vicu\u00f1a R. Anti-citrullinated protein antibody titers are independently modulated by both disease activity and conventional or biologic anti-rheumatic drugs. Diagnostics. 2022;12:1\u201314.","journal-title":"Diagnostics"},{"key":"730_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/cei.12114","volume":"173","author":"S Modi","year":"2013","unstructured":"Modi S, Soejima M, Levesque MC. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol. 2013;173:8\u201317.","journal-title":"Clin Exp Immunol"},{"key":"730_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00296-010-1671-3","volume":"32","author":"K Shidara","year":"2012","unstructured":"Shidara K, Inoue E, Hoshi D, et al. Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. Rheumatol Int. 2012;32:361\u20136.","journal-title":"Rheumatol Int"},{"key":"730_CR34","first-page":"1","volume":"18","author":"YJ Song","year":"2023","unstructured":"Song YJ, Cho SK, Kim H, et al. Factors associated with selection of targeted therapy in patients with rheumatoid arthritis. PLoS ONE. 2023;18:1\u201313.","journal-title":"PLoS ONE"},{"key":"730_CR35","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3899\/jrheum.140082","volume":"41","author":"L Barra","year":"2014","unstructured":"Barra L, Pope JE, Orav JE, et al. Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol. 2014;41:2361\u20139.","journal-title":"J Rheumatol"},{"key":"730_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3904\/kjim.2019.411","volume":"35","author":"EJ Park","year":"2020","unstructured":"Park EJ, Kim H, Jung SM, Sung YK, Baek HJ, Lee J. The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean expert consensus. Korean J Intern Med. 2020;35:41\u201359.","journal-title":"Korean J Intern Med"},{"key":"730_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/rmdopen-2023-003975","volume":"10","author":"C L\u00f3pez-Medina","year":"2024","unstructured":"L\u00f3pez-Medina C, Calvo-Guti\u00e9rrez J, Carmen \u00c1balos-Aguilera M, et al. Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study. RMD Open. 2024;10:1\u20139.","journal-title":"RMD Open"},{"key":"730_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2020.102735","volume":"20","author":"A Conforti","year":"2021","unstructured":"Conforti A, Di Cola I, Pavlych V, et al. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev. 2021;20:1\u201314.","journal-title":"Autoimmun Rev"},{"key":"730_CR39","first-page":"1","volume":"5","author":"BA Kimbrough","year":"2023","unstructured":"Kimbrough BA, Crowson CS, Davis JM, Matteson EL, Myasoedova E. Decline in incidence of extra-articular manifestations of rheumatoid arthritis: a population-based cohort study. Arthritis Care Res (Hoboken). 2023;5:1\u20139.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"730_CR40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.reuma.2017.08.012","volume":"15","author":"Y Cruz-Castillo","year":"2019","unstructured":"Cruz-Castillo Y, Montero N, Salazar-Ponce R, Villac\u00eds-Tamayo R. Quality of life in Ecuadorian patients with rheumatoid arthritis: a cross-sectional study. Reumatol Clin. 2019;15:296\u2013300.","journal-title":"Reumatol Clin"},{"key":"730_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41927-019-0080-9","volume":"3","author":"W Katchamart","year":"2019","unstructured":"Katchamart W, Narongroeknawin P, Chanapai W, Thaweeratthakul P. Health-related quality of life in patients with rheumatoid arthritis. BMC Rheumatol. 2019;3:1\u20138.","journal-title":"BMC Rheumatol"},{"key":"730_CR42","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/1756-185X.12915","volume":"21","author":"SC Bae","year":"2018","unstructured":"Bae SC, Cho SK, Won S, et al. Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months. Int J Rheum Dis. 2018;21:1001\u20139.","journal-title":"Int J Rheum Dis"},{"key":"730_CR43","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.reuma.2017.03.002","volume":"14","author":"D Rosa-Gon\u00e7alves","year":"2018","unstructured":"Rosa-Gon\u00e7alves D, Bernardes M, Costa L. Quality of life and functional capacity in patients with rheumatoid arthritis\u2014cross-sectional study. Reumatol Clin. 2018;14:360\u20136.","journal-title":"Reumatol Clin"},{"key":"730_CR44","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00296-014-2981-7","volume":"34","author":"S Slimani","year":"2014","unstructured":"Slimani S, Abbas A, Ben Ammar A, et al. Characteristics of rheumatoid arthritis in Algeria: a multicenter study. Rheumatol Int. 2014;34:1235\u20139.","journal-title":"Rheumatol Int"},{"key":"730_CR45","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1136\/ard.2005.035691","volume":"64","author":"VPK Nell","year":"2005","unstructured":"Nell VPK, Machold KP, Stamm TA, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005;64:1731\u20136.","journal-title":"Ann Rheum Dis"},{"key":"730_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2498","volume":"10","author":"N Courvoisier","year":"2008","unstructured":"Courvoisier N, Dougados M, Cantagrel A, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2008;10:1\u20139.","journal-title":"Arthritis Res Ther"},{"key":"730_CR47","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/art.10167","volume":"46","author":"M Bukhari","year":"2002","unstructured":"Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register study, a large inception cohort. Arthritis Rheum. 2002;46:906\u201312.","journal-title":"Arthritis Rheum"},{"key":"730_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42358-022-00265-0","volume":"63","author":"CP de Albuquerque","year":"2023","unstructured":"de Albuquerque CP, Reis APMG, Santos ABV, et al. Decreasing delays in the diagnosis and treatment of rheumatoid arthritis in Brazil: a nationwide multicenter observational study. Adv Rheumatol. 2023;63:1\u20138.","journal-title":"Adv Rheumatol"},{"key":"730_CR49","first-page":"1","volume":"11","author":"R Choi","year":"2022","unstructured":"Choi R, Lee SG, Lee EH. Intraindividual changes in rheumatoid factor and anti-cyclic citrullinated peptide antibody tests in Korean patients visiting local clinics and hospitals. J Clin Med. 2022;11:1\u20138.","journal-title":"J Clin Med"},{"key":"730_CR50","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1590\/S0482-50042009000300004","volume":"49","author":"LMH da Mota","year":"2009","unstructured":"da Mota LMH, Neto LLS, Burlingame R, Laurindo IMM. Comportamento distinto dos sorotipos do fator reumatoide em avalia\u00e7\u00e3o seriada de pacientes com artrite reumatoide inicial. Rev Bras Reumatol. 2009;49:223\u201335.","journal-title":"Rev Bras Reumatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00730-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00730-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00730-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T17:35:38Z","timestamp":1737480938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00730-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00730-w","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors\u00a0Victor Davi Rosa e Silva de Oliveira,\u00a0Let\u00edcia Rocha Pereira,\u00a0Manoel Barros B\u00e9rtolo,\u00a0Maria de F\u00e1tima Lobato da Cunha Sauma,\u00a0Paulo Louzada J\u00fanior,\u00a0Cleandro Pires de Albuquerque, and\u00a0Geraldo da Rocha Castelar-Pinheiro\u00a0declare that they have no conflicts of interest.\u00a0Ana Paula Monteiro Gomides Reis: Has received speaking fees and support for educational activities from AbbVie, Pfizer, and Janssen. Has participated in advisory boards for AbbVie and Pfizer.\u00a0Claiton Viegas Brenol: Has participated in clinical and\/or experimental studies related to this work and sponsored by AbbVie, BMS, Janssen, Pfizer, and Roche; has received personal or institutional support from AbbVie, BMS, Janssen, Pfizer, and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, and Roche.\u00a0Iv\u00e2nio Alves Pereira: Has received consulting fees, speaking fees, and support for international congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, AbbVie, and Janssen.\u00a0Following completion of this work, Iv\u00e2nio Alves Pereira has changed affiliation to Universidade do Sul de Santa Catarina.\u00a0Karina Rossi Bonfiglioli: Has received speaking fees and support for educational activities from AbbVie, UCB, Janssen, Pfizer.\u00a0Maria Fernanda Brand\u00e3o de Resende Guimar\u00e3es: Has received speaking fees and support for international congresses from Amgen, AbbVie, UCB, Lilly, and Janssen.\u00a0Rina Dalva Neubarth Giorgi: Has participated in advisory boards and received speaking fees and support for international congresses from Eli Lilly, Biocon, Novartis, Janssen, AbbVie, and Fresenius Kabi.\u00a0Sebasti\u00e3o Cezar Radominski: Has received speaking fees from AbbVie, Janssen, Novartis, and Pfizer; has participated in clinical studies sponsored by AbbVie and Novartis.\u00a0L\u00edcia Maria Henrique da Mota: Has received personal or institutional support from AbbVie, Janssen, Pfizer, and Roche; has delivered speeches at events related to this work and sponsored by AbbVie, Boehringer Ingelheim, GSK, Janssen, Libbs, Lilly, Novartis, Pfizer, Roche, Sandoz, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the National Commission of Ethics in Research (CONEP\u2014Comiss\u00e3o Nacional de \u00c9tica em Pesquisa, Brazilian Ministry of Health) and by institutional review boards of each participating center (protocol number CAAE 45781015.8.1001.5259). All patients provided written informed consent prior to inclusion in the study. The study was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}